InvestorsHub Logo
Post# of 252255
Next 10
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

Re: DewDiligence post# 223285

Monday, 01/21/2019 9:35:25 PM

Monday, January 21, 2019 9:35:25 PM

Post# of 252255

One can see that this clinical failure is significant from an investment standpoint by turning the result on its head: i.e., if the trial in question had succeeded, it would surely have caused a material bump in ABBV’s (and even JNJ’s) valuation. So, the absence of such a bump is itself a notable event.



I disagree, you can't stand it on its head because it's asymmetric.

Failure = expected.
Positive result = wildly unexpected.

When a drug is tested in multiple solid tumor types, pancreatic is always the first to report and is always a failure.

I don't think failure of any drug in pancreatic says anything about its efficacy in other tumor types.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.